Ide-cel Appears Active in Almost Three-Fourths of Heavily Pretreated Patients with Myeloma
The BCMA-targeting CAR T-cell therapy yielded a response in73% of patients with heavily pretreated relapsed/refractory multiple myeloma.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Jason M. Broderick Source Type: news
More News: Cancer & Oncology | Myeloma